<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="therapy. We found limited evidence to support the use of" exact="ondansetron" post="and the treatment of co‐morbid conditions and complementary therapies."/>
 <result pre="to patient at 2‐week intervals. Prophylactic Pediatric Randomized trial of" exact="amitriptyline" post="vs cyproheptadine. MD visits every 2 weeks over 6"/>
 <result pre="3 Hikita et al. (2016) Valproic acid Valproic acid with" exact="phenobarbital" post="Phenobarbital Amitriptyline Phenytoin Carbamazepine Cyproheptadine Primidone Propranolol Clonidine hydrochloride"/>
 <result pre="chart review and patient questionnaire. Turkey 38 (16 patients on" exact="topiramate" post="and 22 patients on propranolol) CVS diagnosed by Rome"/>
 <result pre="specified 7 Treepongkaruna et al. (2014) Amitriptyline Propranolol Cyproheptadine Sodium" exact="valproate" post="(Medication dosages not explicitly stated but prior clinical practice"/>
 <result pre="dosages) Prophylactic Pediatric Retrospective cohort Thailand 29 patients received either" exact="propranolol" post="(n = 11), cyproheptadine (n = 4), and amitriptyline"/>
 <result pre="cohort Thailand 29 patients received either propranolol (n = 11)," exact="cyproheptadine" post="(n = 4), and amitriptyline (n = 14). Long‐term"/>
 <result pre="either propranolol (n = 11), cyproheptadine (n = 4), and" exact="amitriptyline" post="(n = 14). Long‐term outcomes were available in 19"/>
 <result pre="kg, 125 mg if &amp;gt; 60 kg Abortive regimen of" exact="aprepitant" post="given if prodromal phase* suggested imminent CVS attack. Otherwise,"/>
 <result pre="given if prodromal phase* suggested imminent CVS attack. Otherwise, prophylactic" exact="aprepitant" post="dose given. All oral administration. *Prodromal phase= symptoms such"/>
 <result pre="1 gram twice daily, Co‐enzyme Q‐10 200 mg twice daily," exact="riboflavin" post="100 mg once daily) Abortive and prophylactic Adult Retrospective"/>
 <result pre="months. 10 Lee et al. (2012) TCA Propranolol L‐carnitine and" exact="amitriptyline" post="Erythromycin Coenzyme Q Phenobarbital Valproate Pizotifen Cyproheptadine L‐Carnitine Sumatriptan"/>
 <result pre="Propranolol (1 mg/kg per day) Prophylactic Pediatric Randomized trial of" exact="amitriptyline" post="vs propranolol Iran 164 patients (81 on propranolol and"/>
 <result pre="mg/kg per day) Prophylactic Pediatric Randomized trial of amitriptyline vs" exact="propranolol" post="Iran 164 patients (81 on propranolol and 83 on"/>
 <result pre="trial of amitriptyline vs propranolol Iran 164 patients (81 on" exact="propranolol" post="and 83 on amitriptyline) CVS diagnosis: &amp;gt;/= 3 episodes"/>
 <result pre="patients on listed medication Valproic acid (9/4/15) Valproic acid with" exact="phenobarbital" post="(4/0/4) Phenobarbital (3/6/9) Amitriptyline (1/4/5) Phenytoin (0/4/4) Carbamazepine (0/2/2)"/>
 <result pre="success with my treatments.&quot; b) Abortive treatment ‐10/16 (63%) said" exact="ondansetron" post="was most effective abortive medication ‐7/16 (44%) said benzodiazepines"/>
 <result pre="Short‐term outcomes Good response: Amitriptyline 11/15 (73%) (significantly better than" exact="propranolol" post="P = 0.04) Propranolol 5/14 (36%) Cyproheptadine 0/4 (0%)"/>
 <result pre="P = 0.04) Propranolol 5/14 (36%) Cyproheptadine 0/4 (0%) Sodium" exact="valproate" post="1/3 (33%) Long‐term outcomes (diagnosis ≥ 2 years) Data"/>
 <result pre="interval length (days) School attendance percentage Prophylactic group had higher" exact="aprepitant" post="doses than the abortive group. All outcomes below measured"/>
 <result pre="to medication TCA 168/244 (68%) Propranolol 79/91 (87%) L‐carnitine and" exact="amitriptyline" post="23/30 (77%) Erythromycin 13/20 (65%) Coenzyme Q 12/18 (67%)"/>
 <result pre="+ Co‐Q10: Resolution: 3 patients (in one of these cases," exact="amitriptyline" post="was not tolerated, yet episodes resolved on topiramate +"/>
 <result pre="these cases, amitriptyline was not tolerated, yet episodes resolved on" exact="topiramate" post="+ co‐enzyme Q10) Amitriptyline + L‐carnitine: Resolution: 2 patients"/>
 <result pre="treatment was not effective in preventing vomiting) 11 patients received" exact="sumatriptan" post="subcutaneous injection: Complete resolution: 4/11(36%) Effective response: 5/11 (46%)"/>
 <result pre="improvement in VAS at 3 months: 22/27(81%) 24 patients on" exact="amitriptyline" post="for at least 3 months: 93% had a &quot;favorable"/>
 <result pre="good/fair response. Medication &quot;non‐effective&quot; if poor response. Pizotifen: 8/25 received" exact="pizotifen" post="Good response: 3 (2 with mild disease, 1 with"/>
 <result pre="Poor response: 4 (3 had severe disease) In 3 patients," exact="pizotifen" post="changed to amitriptyline Amitriptyline (18/25 patents received) Good response:"/>
 <result pre="(3 had severe disease) In 3 patients, pizotifen changed to" exact="amitriptyline" post="Amitriptyline (18/25 patents received) Good response: 11 (4 with"/>
 <result pre="(1 with severe disease) No statistical difference in response between" exact="pizotifen" post="and amitriptyline No adverse events observed 20 Prakash et"/>
 <result pre="severe disease) No statistical difference in response between pizotifen and" exact="amitriptyline" post="No adverse events observed 20 Prakash et al. (1999)"/>
 <result pre="vs non‐migraine CVS (1/3 (33%). No statistically significant difference in" exact="sumatriptan" post="usage between groups None reported 22 Andersen et al."/>
 <result pre="the randomized trials were converted to a single‐arm cohort of" exact="amitriptyline" post="for inclusion into a summary estimate for amitriptyline's symptomatic"/>
 <result pre="and 29/137 pediatric patients and 13/61 (21%) adult patients discontinued" exact="amitriptyline" post="because of side effects. 7 However, adverse events leading"/>
 <result pre="and imprecision (for a few of the outcomes). 3.2.2 Should" exact="topiramate" post="be used as prophylactic therapy in adults with CVS?"/>
 <result pre="message There is very low certainty in the evidence that" exact="topiramate" post="should be used as prophylactic therapy in CVS. See"/>
 <result pre="See Table 4 for full evidence profile Table 4 Should" exact="topiramate" post="be used as prophylactic therapy in adults with CVS?"/>
 <result pre="In one additional study (Kumar 2012), 17/76 adult patients received" exact="topiramate" post="but there was not enough detail provided for the"/>
 <result pre="the analysis (as patients may also have been treated with" exact="amitriptyline" post="and mitochondrial supplements. In this study, overall response was"/>
 <result pre="One study met inclusion criteria that investigated the role of" exact="topiramate" post="in CVS. 15 Sezer et al. investigated the use"/>
 <result pre="in CVS. 15 Sezer et al. investigated the use of" exact="topiramate" post="(n = 16) and propranolol (n = 22) in"/>
 <result pre="al. investigated the use of topiramate (n = 16) and" exact="propranolol" post="(n = 22) in 38 pediatric patients with CVS"/>
 <result pre="in a retrospective cohort study in Turkey. At baseline, the" exact="topiramate" post="group (compared to the propranolol group) had significantly fewer"/>
 <result pre="in Turkey. At baseline, the topiramate group (compared to the" exact="propranolol" post="group) had significantly fewer episodes of vomiting/cycle before treatment,"/>
 <result pre="of emeses/hour during an attack. As such, patients in the" exact="topiramate" post="group might have been less severe prior to treatment"/>
 <result pre="might have been less severe prior to treatment than the" exact="propranolol" post="group. Patients were followed for 1 year. At follow‐up,"/>
 <result pre="≥ 50% reduction in attacks) were significantly higher in the" exact="topiramate" post="group 15/16 (94%) compared to the propranolol group 18/22"/>
 <result pre="higher in the topiramate group 15/16 (94%) compared to the" exact="propranolol" post="group 18/22 (81%). In the topiramate arm, 81% became"/>
 <result pre="(94%) compared to the propranolol group 18/22 (81%). In the" exact="topiramate" post="arm, 81% became episode free and 13% showed at"/>
 <result pre="Per the study, the four patients who were non‐responsive to" exact="propranolol" post="were treated with topiramate, and all of them had"/>
 <result pre="by the authors. The one patient who was non‐responsive to" exact="topiramate" post="was also non‐responsive to other medications, including propranolol, amitriptyline,"/>
 <result pre="including propranolol, amitriptyline, and cyproheptadine. One additional study reported on" exact="topiramate" post="use in adults (Kumar et al.); in this study,"/>
 <result pre="not enough detail was provided to discern the efficacy of" exact="topiramate" post="alone, as patients in this cohort also received treatment"/>
 <result pre="alone, as patients in this cohort also received treatment with" exact="amitriptyline" post="and mitochondrial supplements. 12 In the study by Sezer"/>
 <result pre="and no statistically significant difference in adverse events between the" exact="propranolol" post="and topiramate groups. 15 Two patients experienced drowsiness and"/>
 <result pre="statistically significant difference in adverse events between the propranolol and" exact="topiramate" post="groups. 15 Two patients experienced drowsiness and dizziness with"/>
 <result pre="and indirectness (the study population was pediatric patients) 3.2.3 Should" exact="aprepitant" post="be used as prophylactic therapy in adults with CVS?"/>
 <result pre="very low certainty in the evidence for the use of" exact="aprepitant" post="as prophylactic therapy in CVS. See Table 5 for"/>
 <result pre="See Table 5 for full evidence profile Table 5 Should" exact="aprepitant" post="be used as prophylactic therapy in adults with CVS?"/>
 <result pre="Ltd, Potential benefits/harms One observational study investigated the use of" exact="aprepitant" post="both as abortive therapy and as prophylactic therapy in"/>
 <result pre="Forty‐one children and adolescents were included with 25 being administered" exact="aprepitant" post="as an abortive medication and 16 as prophylaxis. Some"/>
 <result pre="no control group. Patients were given an &quot;abortive&quot; regimen of" exact="aprepitant" post="if they had a prodromal phase that suggested an"/>
 <result pre="With respect to co‐interventions, individuals were also being treated with" exact="propranolol" post="9/15 (60%), amitriptyline 7/15 (46%), coenzyme Q10 5/15 (33%),"/>
 <result pre="co‐interventions, individuals were also being treated with propranolol 9/15 (60%)," exact="amitriptyline" post="7/15 (46%), coenzyme Q10 5/15 (33%), and L‐carnitine 3/15"/>
 <result pre="dosed accordingly, making this less of a concern. 3.2.4 Should" exact="zonisamide" post="or levetiracetam be used as prophylactic therapy in adults"/>
 <result pre="making this less of a concern. 3.2.4 Should zonisamide or" exact="levetiracetam" post="be used as prophylactic therapy in adults with CVS?"/>
 <result pre="very low certainty in the evidence for the use of" exact="zonisamide" post="or levetiracetam as prophylactic therapy. See Table 6 for"/>
 <result pre="certainty in the evidence for the use of zonisamide or" exact="levetiracetam" post="as prophylactic therapy. See Table 6 for full evidence"/>
 <result pre="Table 6 for full evidence profile Table 6 Should (antiepileptics)" exact="zonisamide" post="or levetiracetam be used as prophylactic therapy in adults"/>
 <result pre="for full evidence profile Table 6 Should (antiepileptics) zonisamide or" exact="levetiracetam" post="be used as prophylactic therapy in adults with CVS?"/>
 <result pre="Serious [Link] None Severe AEs: 4/20 (20%). One subject on" exact="levetiracetam" post="developed angioedema, which resolved when switched to zonisamide. One"/>
 <result pre="the 20 patients with a &quot;favorable&quot; clinical response, 12/16 received" exact="zonisamide" post="and 3/4 received levetiracetam. This retrospective study was based"/>
 <result pre="of 20 adult patients with CVS who had received prophylactic" exact="zonisamide" post="(median dose, 400 mg/day) or levetiracetam (median dose, 1000"/>
 <result pre="who had received prophylactic zonisamide (median dose, 400 mg/day) or" exact="levetiracetam" post="(median dose, 1000 mg/day) when tricyclic antidepressants (TCAs) alone"/>
 <result pre="failed, were intolerable, or unsuitable. Sixteen patients were treated with" exact="zonisamide" post="and four with levetiracetam for CVS prophylactic therapy. Median"/>
 <result pre="unsuitable. Sixteen patients were treated with zonisamide and four with" exact="levetiracetam" post="for CVS prophylactic therapy. Median follow‐up after initiation of"/>
 <result pre="satisfaction with therapy. Twelve out of 16 patients in the" exact="zonisamide" post="group and 3 out of 4 in the levetiracetam"/>
 <result pre="the zonisamide group and 3 out of 4 in the" exact="levetiracetam" post="group reported a favorable clinical response. Frequency of vomiting"/>
 <result pre="Frequency of vomiting episodes decreased significantly after initiation of either" exact="zonisamide" post="or levetiracetam from 1.3 to 0.5 episodes/month. In total,"/>
 <result pre="vomiting episodes decreased significantly after initiation of either zonisamide or" exact="levetiracetam" post="from 1.3 to 0.5 episodes/month. In total, 18/20 (90%)"/>
 <result pre="of the 4 patients was on a high dose of" exact="levetiracetam" post="(3000 mg/day). Five subjects out of 20 reported depression,"/>
 <result pre="sleeping, dizziness, poor concentration/memory, confusion, or tiredness/fatigue. One subject on" exact="levetiracetam" post="developed angioedema, which resolved when switched to zonisamide. Only"/>
 <result pre="the use of mitochondrial supplements, such as Co‐enzyme Q10, and" exact="riboflavin" post="as prophylactic therapy. See Table 7 for full evidence"/>
 <result pre="study, the authors compared the efficacy of Coenzyme Q10 to" exact="amitriptyline" post="in patients with CVS via an Internet‐based survey that"/>
 <result pre="self‐selection bias. No published studies reported on the efficacy of" exact="riboflavin" post="in CVS patients. The Boles 2011 study included riboflavin"/>
 <result pre="of riboflavin in CVS patients. The Boles 2011 study included" exact="riboflavin" post="but did not report on response for these patients."/>
 <result pre="54% of attacks in 11 kids/1 adult were responsive to" exact="sumatriptan" post="therapy (defined as complete improvement or at least a"/>
 <result pre="effective in preventing vomiting). For the 11 patients receiving subcutaneous" exact="sumatriptan" post="injection, 4/11 had complete resolution, 5/11 had effective response,"/>
 <result pre="episodes) with subcutaneous sumatriptan. Indirect estimates for the effect of" exact="sumatriptan" post="on symptom reduction (nausea and vomiting) were derived from"/>
 <result pre="higher rates of symptom improvement were seen in individuals receiving" exact="sumatriptan" post="by either intranasal (50%‐60% range) and subcutaneous routes (76%)."/>
 <result pre="adults with CVS? No published studies examining the use of" exact="ondansetron" post="as abortive therapy for CVS were identified despite its"/>
 <result pre="in CVS. No GRADE evidence profile was created. 3.3.3 Should" exact="aprepitant" post="be used as abortive therapy in adults with CVS?"/>
 <result pre="very low certainty in the evidence for the use of" exact="aprepitant" post="as abortive therapy. See Table 9 for full evidence"/>
 <result pre="See Table 9 for full evidence profile Table 9 Should" exact="aprepitant" post="be used as abortive therapy in adults with CVS?"/>
 <result pre="Ltd, Potential benefits/harms One observational study investigated the use of" exact="aprepitant" post="as abortive therapy and as prophylactic therapy in CVS."/>
 <result pre="well as telephone interviews with patients’ parents (see section on" exact="aprepitant" post="as prophylactic therapy in CVS for more details). In"/>
 <result pre="the abortive group. There were no noted adverse events from" exact="aprepitant" post="administration in the abortive group. Certainty in the evidence"/>
 <result pre="the committee relied on indirect evidence on the efficacy of" exact="ondansetron" post="in patients with chemotherapy‐induced nausea and vomiting (CINV) and"/>
 <result pre="Effective prophylactic therapy for cyclic vomiting syndrome in children using" exact="amitriptyline" post="or cyproheptadine . Pediatrics. 1997; 100: 977‐ 981. 9374568"/>
 <result pre="therapy for cyclic vomiting syndrome in children using amitriptyline or" exact="cyproheptadine" post=". Pediatrics. 1997; 100: 977‐ 981. 9374568 6 Badihian"/>
 <result pre="E , et al. Efficacy of the neurokinin‐1 receptor antagonist" exact="aprepitant" post="in children with cyclical vomiting syndrome . Aliment Pharmacol"/>
 <result pre="GS , Lustman PJ , Prakash C . Zonisamide or" exact="levetiracetam" post="for adults with cyclic vomiting syndrome: a case series."/>
</results>
